Cushing syndrome and severe adrenal suppression caused by fluticasone and protease inhibitor combination in an HIV-infected adolescent

AIDS Patient Care and STDs

Volumn 21, Issue 6, 2007, Pages 373-377

  St Germain, Renee M ^a,b   Yigit, Sevket ^b,c   Wells, Lorraine ^b   Giratto, Jennifer E ^a,b   Salazar, Juan C ^a,b,c  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b Farmington   (United States)

^c UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; CYTOCHROME P450; DIDANOSINE; FLUTICASONE; HYDROCORTISONE; MONTELUKAST; PROTEINASE INHIBITOR; RITONAVIR; SALMETEROL; STEROID; TENOFOVIR;

ADOLESCENT; ADRENAL INSUFFICIENCY; ADRENAL SUPPRESSION; ARTICLE; ASTHMA; CASE REPORT; CUSHING DISEASE; CUSHING SYNDROME; CUSHINGOID SYNDROME; DISEASE SEVERITY; DRUG MEGADOSE; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; HEADACHE; HEALTH CARE PERSONNEL; HORMONE SUBSTITUTION; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCORTISOLISM; MOON FACE; MUSCLE WEAKNESS; NARANJO PROBABILITY SCALE; PATHOGENESIS; SCORING SYSTEM; SIDE EFFECT; SYSTEMIC THERAPY; TREATMENT OUTCOME; WEIGHT GAIN;

ADOLESCENT; ADRENAL INSUFFICIENCY; ALBUTEROL; ANDROSTADIENES; ANTI-HIV AGENTS; ANTI-INFLAMMATORY AGENTS; CUSHING SYNDROME; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; HYDROCORTISONE; OLIGOPEPTIDES; PYRIDINES; RITONAVIR;

EID: 34250870669     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2006.0117     Document Type: Article

References (26)

1. Panel on Clinical Practices for the Treatment of HIV infection convened by the Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. October 6, 2005.
2. Gavin PJ, Yogev R. The role of protease inhibitor therapy in children with HIV infection. Paediatr Drugs 2002;4:581-607.
3. Working Group on Antiretroviral Therapy and Medical Management of HIV-infected Children convened by the National Resource Center at the Francois-Xavier Bagnoud Center, UMDNJ. The Health Resources and Services Administration (HRSA); and the National Institutes of Health. Guidelines for the use of antiretroviral agents in pediatric HIV infection. November 3, 2005.
4. Gortmaker S, Hughes M, Cervia J, Brady M, et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV. N Engl J Med 2001;345:1522-1528.
5. Clevenbergh P, Corcostegui M, Gerard D, et al. Iatrogenic Cushing's syndrome in an HIV-infected patient treated with inhaled corticosteroids (fluticasone propionate) and low dose ritonavir enhanced PI containing regimen. J Infect 2002;44194-195.
6. von Moltke L, Greenblatt D, Grassi J, et al. Protease inhibitors as inhibitors of human cytochromes p450: High risk associated with ritonavir. J Clin Pharmacol 1998;38:106-111.
7. Samaras K, Pett S, Gowers A, McMurchie M, Cooper DA. Iatrogenic Cushing's syndrome with osteoporosis and secondary adrenal failure in human immunodeficiency virus-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: Six cases. J Clin Endocrinol Metab 2005;90:4394-4398.
8. Gillett MJ, Cameron PU, Nguyen HV, Hurley DM, Mallal SA. Iatrogenic Cushing's syndrome in an HIV-infected patient treated with ritonavir and inhaled fluticasone. AIDS 2005;19:740-741.
9. Malaty L, Kuper J. Drug interactions of HIV protease inhibitors. Drug Saf 1999;20:147-169.
10. Williams SG, Schmidt DK, Redd SC, Storms W. Key clinical activities for quality asthma care. Recommendations of the National Asthma Education and Prevention Program. MMWR Recomm Rep 2003;52:1-8.
11. National Heart L, and Blood Institute, National Asthma Education and Prevention Program. Guidelines for the diagnosis and management of asthma-update on selected topics 2002. J Allergy Clin Immunol 2002;110:S142-219.
12. Whelan GJ, Blumer JL, Martin RJ, Szefler SJ. Fluticasone propionate plasma concentration and systemic effect: Effect of delivery device and duration of administration. J Allergy Clin Immunol 2005;116:525-530.
13. Chen F, Kearney T, Robinson S, Daley-Yates PT, Waldron S, Churchill DR. Cushing's syndrome and severe adrenal suppression in patients treated with ritonavir and inhaled nasal fluticasone. Sex Transm Infect 1999;75:274.
14. Gupta SK, Dube MP. Exogenous cushing syndrome mimicking human immunodeficiency virus lipodystrophy. Clin Infect Dis 2002;35:E69-71.
15. Hillebrand-Haverkort ME, Prummel MF, ten Veen JH. Ritonavir-induced Cushing's syndrome in a patient treated with nasal fluticasone. AIDS 1999;13:1803.
16. Rouanet I, Peyriere H, Mauboussin JM, Vincent D. Cushing's syndrome in a patient treated by ritonavir/lopinavir and inhaled fluticasone. HIV Med 2003;4:149-150.
17. Soldatos G, Sztal-Mazer S, Woolley I, Stockigt J. Exogenous glucocorticoid excess as a result of ritonavir-fluticasone interaction. Intern Med J 2005;35:67-68.
18. leRoux C, Beckles M, Besser G, Pinching A, Davison A. Cushing's syndome secondary to inhaled corticosteroid mimicking HIV-associated lipodystrophy. HIV Med 2001;2:133-135.
19. Naranjo C, Busto U, Sellers E, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-245.
20. European Paediatric Lipodystrophy Group. Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe. AIDS 2004;18:1443-1451.
21. Licata AA. Systemic effects of fluticasone nasal spray: Report of 2 cases. Endocr Pract 2005;11:194-196.
22. Lin ML, Min SS, Eron JJ, et al. Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome p-450 induction. J Acquir Immune Defic Syndr 2004;36:1034-1040.
23. Crommentuyn KM, Mulder JW, Sparidans RW, Huitema ADR, Schellens JHM, Beijnen JH. Drug-drug interaction between itraconazole and the antiretroviral drug lopinavir/ritonavir in an HIV-1-infected patient with disseminated histoplasmosis. Clin Infect Dis 2004;38:e73-75.
24. Romanelli F, Ryan M. Concurrent use of antiretrovirals and anticonvulsants in a rural population. AIDS Patient Care STDs 2002;16:101-102.
25. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy. Arch Intern Med 1999;159:941-955.
26. Advair Diskus Package Insert. Research Triangle Park, NC: GlaxoSmithKIine, September 2004.